查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1954259

病毒载体生产市场分析及预测（至2035年）：依类型、产品类型、服务、技术、应用、最终用户、製程、阶段、设备划分

Viral Vector Production Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Stage, Equipment
出版日期: | 出版商: Global Insight Services | 英文 312 Pages | 商品交期: 3-5个工作天内

价格
简介目录

病毒载体生产市场预计将从2024年的76亿美元成长到2034年的457亿美元，复合年增长率约为22.1%。病毒载体生产市场涵盖用于基因治疗、疫苗和细胞治疗的病毒载体的生产和供应。这些载体对于将遗传物质递送到细胞中至关重要，从而实现治疗性介入。生物技术的进步和对个人化医疗投资的增加是推动市场成长的主要因素。关键趋势包括可扩展生产技术的开发和对创新治疗方法的监管支持，这些因素正在促进市场成长并形成差异化竞争优势。

病毒载体生产市场持续稳定成长，主要受基因治疗和疫苗研发进展的推动。基因治疗领域凭藉临床试验的增加和FDA核准的进展，成为成长最快的细分市场。慢病毒载体因其能够整合到宿主基因组中，确保长期表达，占据市场主导地位。腺结合病毒载体因其安全性高且无致病性而备受推崇，是成长第二快的细分市场。在疫苗研发中，病毒载体对于有效递送抗原至关重要。腺病毒载体细分市场占据主导地位，尤其是在新冠疫苗生产领域，这主要得益于其快速的生产能力。虽然逆转录病毒载体的应用相对较少，但其在肿瘤学领域的潜在应用正在推动市场成长。生物技术公司与学术机构之间日益密切的合作正在推动创新，并提高载体的设计和生产效率。持续投资于可扩展的生产技术至关重要，这能够确保市场的持续发展，并满足未来的治疗需求。

市场区隔
类型 腺病毒载体、慢病毒载体、腺结合病毒载体、逆转录病毒载体
产品 质体，表现系统
服务 上游工程、下游製程、品管与测试
科技 转染，转导
应用领域 基因疗法、疫苗学、细胞疗法、癌症研究
最终用户 生物製药公司、研究机构和契约製造组织
过程 发酵和精炼
步 临床前、临床和商业化生产
装置 生物反应器、离心机、过滤系统

病毒载体生产市场正经历市场份额、定价策略和产品创新方面的动态变化。各公司正透过尖端病毒载体解决方案来增强产品系列，以满足基因治疗和疫苗研发的激增需求。先进生物製程技术的趋势正在影响定价结构，使其更加重视成本效益和扩充性。新产品的推出正在建立疗效和安全性的新标准，进一步加剧了市场竞争。这种演变反映了业界为满足不断增长的临床和商业性需求所做的努力。病毒载体生产市场的竞争日益激烈，主要参与者都在寻求技术优势。基准分析显示，旨在增强生产能力的策略联盟和併购正成为主流。法规结构，尤其是在美国和欧洲，对于确保合规性和品质标准以及塑造市场动态至关重要。亚太地区的新兴市场在有利的政府政策和不断增长的医疗保健投资的推动下，提供了盈利的机会。预计在创新和策略联盟的支持下，该市场将实现强劲成长。

主要趋势和驱动因素：

受基因疗法和疫苗需求不断增长的推动，病毒载体生产市场正经历强劲增长。生物技术的进步催生了更有效率、扩充性的病毒载体生产技术。遗传性疾病和感染疾病的日益增多，对创新疗法的需求也进一步推动了这一趋势。关键趋势包括采用一次性技术，这提高了生产的柔软性并降低了污染风险。此外，人工智慧 (AI) 和自动化技术在生产流程中的应用，也提高了营运效率和产量。旨在扩大产能和加快新治疗方法上市速度的策略联盟和伙伴关係也激增。推动市场成长的因素包括製药公司的大量投资以及政府对先进治疗药物 (ATMP) 的支持。个人化医疗和客製化治疗的推进，进一步刺激了对病毒载体的需求。能够在保证品质和符合监管要求的前提下扩大生产规模的公司，将更有机会掌握这些盈利的机会。不断扩充的细胞和基因疗法研发管线有望显着改善医疗保健效果，凸显了市场的巨大潜力。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 腺病毒载体
    • 慢病毒载体
    • 腺结合病毒载体
    • 逆转录病毒载体
  • 市场规模及预测：依产品划分
    • 质体
    • 表达系统
  • 市场规模及预测：依服务划分
    • 上游工程
    • 下游工艺
    • 品管和测试
  • 市场规模及预测：依技术划分
    • 转染
    • 转导
  • 市场规模及预测：依应用领域划分
    • 基因治疗
    • 疫苗学
    • 细胞疗法
    • 癌症研究
  • 市场规模及预测：依最终用户划分
    • 生物製药公司
    • 研究所
    • 契约製造组织（CMO）
  • 市场规模及预测：依製程划分
    • 发酵
    • 纯化
  • 市场规模及预测：依发展阶段划分
    • 临床前阶段
    • 临床
    • 商业的
  • 市场规模及预测：依设备划分
    • 生物反应器
    • 离心机
    • 过滤系统

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Oxford Biomedica
  • Brammer Bio
  • Genethon
  • VGXI
  • Bio NTech
  • Sirion Biotech
  • Cobra Biologics
  • Cell and Gene Therapy Catapult
  • Yposkesi
  • Mol Med
  • Fin Vector
  • Lonza
  • Batavia Biosciences
  • Novasep
  • Vigene Biosciences
  • Aldevron
  • Bluebird Bio
  • uni Qure
  • Touchlight Genetics
  • Repligen

第九章：关于我们

简介目录
Product Code: GIS31585

Viral Vector Production Market is anticipated to expand from $7.6 billion in 2024 to $45.7 billion by 2034, growing at a CAGR of approximately 22.1%. The Viral Vector Production Market encompasses the manufacturing and supply of viral vectors used in gene therapy, vaccines, and cell therapy. These vectors are pivotal in delivering genetic material into cells, facilitating therapeutic interventions. The market is driven by advancements in biotechnology and increased investment in personalized medicine. Key trends include the development of scalable production technologies and regulatory support for innovative therapies, propelling growth and fostering competitive differentiation.

The Viral Vector Production Market is experiencing robust expansion, primarily propelled by advancements in gene therapy and vaccine development. The gene therapy segment stands out as the top-performing sub-segment, driven by increasing clinical trials and FDA approvals. Lentiviral vectors are leading due to their ability to integrate into the host genome, ensuring long-term expression. Adeno-associated viral vectors are the second highest-performing, favored for their safety profile and non-pathogenic nature. In the vaccine development segment, viral vectors are crucial for delivering antigens effectively. The adenoviral vector sub-segment dominates, especially in COVID-19 vaccine production, due to its rapid manufacturing capabilities. Retroviral vectors, although less prominent, hold potential in oncology applications, contributing to market growth. The rise in partnerships between biotech firms and academic institutions is fostering innovation, enhancing vector design and production efficiency. Continuous investment in scalable manufacturing technologies is pivotal, ensuring the market's sustained evolution and addressing future therapeutic demands.

Market Segmentation
TypeAdenoviral Vectors, Lentiviral Vectors, Adeno-associated Viral Vectors, Retroviral Vectors
ProductPlasmids, Expression Systems
ServicesUpstream Processing, Downstream Processing, Quality Control & Testing
TechnologyTransfection, Transduction
ApplicationGene Therapy, Vaccinology, Cell Therapy, Cancer Research
End UserBiopharmaceutical Companies, Research Institutes, Contract Manufacturing Organizations
ProcessFermentation, Purification
StagePreclinical, Clinical, Commercial
EquipmentBioreactors, Centrifuges, Filtration Systems

The Viral Vector Production Market is witnessing a dynamic shift in market share, pricing strategies, and product innovations. Companies are enhancing their portfolios with cutting-edge viral vector solutions, addressing the burgeoning demand in gene therapy and vaccine development. The trend towards advanced bioprocessing techniques is influencing pricing structures, with a focus on cost-efficiency and scalability. New product launches are setting benchmarks in efficacy and safety, further propelling market competitiveness. This evolution reflects the industry's commitment to meeting the growing clinical and commercial needs. Competition in the viral vector production market is intensifying, with key players striving for technological supremacy. Benchmarking reveals a landscape dominated by strategic partnerships and mergers, aiming to bolster production capabilities. Regulatory frameworks, particularly in the U.S. and Europe, are pivotal in shaping market dynamics, ensuring compliance and quality standards. Emerging markets in Asia-Pacific present lucrative opportunities, driven by favorable government policies and increasing healthcare investments. The market is poised for robust growth, underpinned by innovation and strategic collaborations.

Geographical Overview:

The viral vector production market is witnessing substantial growth across diverse regions, each exhibiting unique opportunities. North America leads the market, propelled by robust biotechnology and pharmaceutical sectors. The region benefits from substantial R&D investments and advanced healthcare infrastructure. The United States, in particular, is a key player, driving innovation and production capabilities. Europe follows, characterized by strong regulatory frameworks and a focus on gene therapy advancements. The United Kingdom and Germany are at the forefront, fostering a conducive environment for viral vector development. In the Asia Pacific region, the market is expanding rapidly due to increasing healthcare investments and a burgeoning biotechnology industry. China and India are emerging as significant contributors, with growing capabilities in biopharmaceutical manufacturing. Latin America and the Middle East & Africa represent emerging growth pockets. In Latin America, Brazil is gaining traction with investments in biotechnology. Meanwhile, the Middle East & Africa are recognizing the potential of viral vectors in addressing regional healthcare challenges, spurring market interest.

Global tariffs and geopolitical tensions are significantly influencing the Viral Vector Production Market, particularly in East Asia. Japan and South Korea are bolstering their biotech sectors to mitigate reliance on foreign imports, while China is rapidly advancing its domestic capabilities in response to Western export controls. Taiwan, crucial for biotech components, is navigating geopolitical pressures with strategic partnerships. The global market for viral vectors, integral to gene therapies and vaccines, is expanding robustly, driven by innovation and increased healthcare spending. By 2035, the market is expected to witness substantial growth, contingent on resilient supply chains and regional collaborations. Middle East conflicts exacerbate global supply chain vulnerabilities and energy price volatility, potentially impacting production costs and timelines for biotech projects worldwide.

Key Trends and Drivers:

The Viral Vector Production Market is experiencing robust growth due to increasing demand for gene therapies and vaccines. Advances in biotechnology have paved the way for more efficient and scalable viral vector production techniques. This trend is further bolstered by the rising prevalence of genetic disorders and infectious diseases, necessitating innovative treatment solutions. Key trends include the adoption of single-use technologies that enhance manufacturing flexibility and reduce contamination risks. Additionally, the integration of artificial intelligence and automation in production processes is streamlining operations and improving yield efficiencies. The market is also witnessing a surge in strategic collaborations and partnerships aimed at expanding production capacities and accelerating time-to-market for new therapies. Drivers of market growth include substantial investments from pharmaceutical companies and government initiatives supporting advanced therapy medicinal products (ATMPs). The push towards personalized medicine and tailored treatment approaches is further amplifying the demand for viral vectors. Companies that can scale production while maintaining quality and regulatory compliance are poised to capitalize on these lucrative opportunities. The expanding pipeline of cell and gene therapies underscores the market's potential, promising significant advancements in healthcare outcomes.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Equipment

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Adenoviral Vectors
    • 4.1.2 Lentiviral Vectors
    • 4.1.3 Adeno-associated Viral Vectors
    • 4.1.4 Retroviral Vectors
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Plasmids
    • 4.2.2 Expression Systems
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Upstream Processing
    • 4.3.2 Downstream Processing
    • 4.3.3 Quality Control & Testing
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Transfection
    • 4.4.2 Transduction
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Gene Therapy
    • 4.5.2 Vaccinology
    • 4.5.3 Cell Therapy
    • 4.5.4 Cancer Research
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Biopharmaceutical Companies
    • 4.6.2 Research Institutes
    • 4.6.3 Contract Manufacturing Organizations
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Fermentation
    • 4.7.2 Purification
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Preclinical
    • 4.8.2 Clinical
    • 4.8.3 Commercial
  • 4.9 Market Size & Forecast by Equipment (2020-2035)
    • 4.9.1 Bioreactors
    • 4.9.2 Centrifuges
    • 4.9.3 Filtration Systems

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Stage
      • 5.2.1.9 Equipment
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Stage
      • 5.2.2.9 Equipment
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Stage
      • 5.2.3.9 Equipment
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Stage
      • 5.3.1.9 Equipment
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Stage
      • 5.3.2.9 Equipment
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Stage
      • 5.3.3.9 Equipment
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Stage
      • 5.4.1.9 Equipment
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Stage
      • 5.4.2.9 Equipment
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Stage
      • 5.4.3.9 Equipment
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Stage
      • 5.4.4.9 Equipment
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Stage
      • 5.4.5.9 Equipment
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Stage
      • 5.4.6.9 Equipment
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Stage
      • 5.4.7.9 Equipment
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Stage
      • 5.5.1.9 Equipment
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Stage
      • 5.5.2.9 Equipment
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Stage
      • 5.5.3.9 Equipment
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Stage
      • 5.5.4.9 Equipment
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Stage
      • 5.5.5.9 Equipment
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Stage
      • 5.5.6.9 Equipment
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Stage
      • 5.6.1.9 Equipment
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Stage
      • 5.6.2.9 Equipment
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Stage
      • 5.6.3.9 Equipment
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Stage
      • 5.6.4.9 Equipment
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Stage
      • 5.6.5.9 Equipment

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Oxford Biomedica
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Brammer Bio
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Genethon
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 VGXI
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Bio NTech
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Sirion Biotech
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Cobra Biologics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Cell and Gene Therapy Catapult
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Yposkesi
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Mol Med
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Fin Vector
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Lonza
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Batavia Biosciences
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Novasep
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Vigene Biosciences
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Aldevron
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Bluebird Bio
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 uni Qure
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Touchlight Genetics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Repligen
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us